The Concept of Treatment in Lysosomal Storage Diseases

  • Roscoe O. Brady

Even though sporadic reports of individual patients who were later classified having a lysosomal storage disease began to appear toward the end of the 19th century (Tay, 1881; Gaucher, 1882; Sachs, 1887), little was known about the true nature of storage materials in the LSDs until the early third of the 20th century. In 1907, F. Marchand reported that a hyaline-like material was stored in the “so-called idiopathic splenomegaly” of the Gaucher type. However, he erroneously believed that it was not a lipid because the material did not react with osmic acid. The accumulating substance was identified as a cerebroside by Lieb in 1924. Cerebrosides consist of three components: two are lipids (sphingosine and fatty acid), and the third is a carbohydrate. Galactocerebroside had been known since the beginning of this century to be the preponderant lipid of the brain on a weight basis. Lieb believed that this cerebroside accumulated in the organs and tissues of patients with Gaucher disease. However, the optical rotation of an aqueous solution of the sugar derived from the accumulating cerebroside was incompatible with its being galactose. In 1934, Aghion reported that the sugar moiety of the accumulating cerebroside was glucose rather than galactose. This finding was confirmed by many investigators, thereby conclusively establishing that the principal accumulating lipid in patients with Gaucher disease is glucocerebroside.


Enzyme Replacement Therapy Fabry Disease Gauche Disease Lysosomal Storage Disease Spleen Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Achord DT, Brot FE, Bell CE, Sly WS. Human beta-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell. 1978; Sep;15(1): 269-278.CrossRefPubMedGoogle Scholar
  2. Aghion, H. La maladie de Gaucher dans l’enfance. 1934; Thèse, Paris.Google Scholar
  3. Barton NW, Brady RO, Dambrosia JM, DiBisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991; 324: 1464-1470.PubMedCrossRefGoogle Scholar
  4. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA. 1990; 87: 1913-1916.CrossRefPubMedGoogle Scholar
  5. Barranger JA, Ohashi T, Hong CM, et al. Molecular pathology and therapy of Gaucher disease. Jpn J Inherit Metabol Dis. 1989; 51: 45-71.Google Scholar
  6. Barranger JA, Pentchev PG, Furbish FS, Steer CJ, Jones EA, Brady RO. Studies of lysosomal function: I. Metabolism of some complex lipids by isolated hepatocytes and Kupffer cells. Biochem Biophys Res Commun. 1978 Aug 14; 83(3): 1055-1060.CrossRefPubMedGoogle Scholar
  7. Barranger JA, Rapoport SI, Fredericks WR, Pentchev PG, MacDermot KD, Steusing JK, Brady RO. Modification of the blood-brain barrier: increased concentration and fate of enzymes entering the brain. Proc Natl Acad Sci USA. 1979 Jan; 76(1): 481-485.CrossRefPubMedGoogle Scholar
  8. Brady, RO. Sphingolipidoses. N Engl J Med. 1966c; 275: 312-318.Google Scholar
  9. Brady RO, Gal AE, Bradley RM, Martensson, E, Warshaw AL, Laster L. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficency. N Engl J Med. 1967; 276: 1163-1167.PubMedGoogle Scholar
  10. Brady RO, Gal AE, Kanfer JN, Bradley RM. The metabolism of cerebrosides. III. Purification and properties of a glucosyl- and galactosylceramide-cleaving enzyme from rat intestinal tissue. J. Biol. Chem. 1965; 240: 3766-3770.PubMedGoogle Scholar
  11. Brady RO, Kanfer JN, Bradley RM, Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease. J. Clin. Inves. 1966a; 45: 1112-1115.CrossRefGoogle Scholar
  12. Brady RO, Kanfer JN, Mock MB, Fredrickson DS. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc. Natl. Acad. Sci. USA. 1966b; 55: 366-369.CrossRefGoogle Scholar
  13. Brady RO, Kanfer J, Shapiro D. The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J. Biol. Chem. 1965a; 240: 39-42.Google Scholar
  14. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem. Biophys. Res. Commun. 1965b; 18: 221-225.Google Scholar
  15. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS, Replacement therapy for inherited enzyme deficiency: Use of purified glucocerebrosidase in Gaucher’s disease. N Engl J. Med. 1974; 291: 989-993.PubMedCrossRefGoogle Scholar
  16. Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WE, Quirk JM, Dekaban AS, Replacement therapy for inherited enzyme deficiency: Use of purified ceramidetrihexosidase in Fabry’s disease. N Engl J Med. 1973; 289: 9-14.PubMedCrossRefGoogle Scholar
  17. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. International Collaborative Fabry Disease Study Group Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med. 2001; 345: 9-16.CrossRefPubMedGoogle Scholar
  18. Furbish FS, Blair HE, Shiloach J, Pentchev PG, Brady RO. Enzyme replacement therapy in Gaucher’s disease: Large-scale purification of glucocerebrosidase suitable for human administration. Proc Natl Acad Sci USA. 1977; 74: 3560-3563.CrossRefPubMedGoogle Scholar
  19. Furbish FS, Steer CJ, Barranger JA, Jones EA, Brady RO. The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochem Biophys Res Commun. 1978 Apr;14; 81(3): 1047-1053.CrossRefPubMedGoogle Scholar
  20. Furbish FS, Steer CJ, Krett NL, Barranger, JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta. 1981; 673: 425-434.PubMedGoogle Scholar
  21. Gaucher PCE. De l’épithélioma primitif de la rate. 1882: Thèse de Paris.Google Scholar
  22. Ginns EI, Choudary PV, Martin BM, Winfield S, Stubblefield B, Mayor J, Merkle-Lehman D, Murray GJ, Bowers LA, Barranger JA. Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda gt11 expression system. Biochem Biophys Res Commun. 1984 Sep 17; 123(2): 574-580.CrossRefPubMedGoogle Scholar
  23. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA et al. Enzyme therapy in Gaucher disease Type 1: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Int Med. 1995; 122: 33-39.PubMedGoogle Scholar
  24. Johnson WG, Brady RO. Ceramidetrihexosidase from human placenta. Methods Enzymol. 1972; XXVIII: 849-856.CrossRefGoogle Scholar
  25. Johnson WG, Desnick RJ, Long DM, Sharp HL, Krivit W, Brady B, Brady RO. Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. Enzyme Therapy in Genetic Diseases. In: Desnick RJ, Bernlohr RW, Krivit W. eds. Baltimore: Williams and Wilkins: 1973: 120-124. Birth Defects Original Article Series, IX.Google Scholar
  26. Kampine JP, Brady RO, Yankee RA, Kanfer JN, Shapiro D, Gal AE. Sphingolipid hydrolases in leukemic leukocytes. Cancer Res. 1967; 27: 1312-1315.PubMedGoogle Scholar
  27. Kanfer JN, Young OM, Shapiro D, Brady RO. The metabolism of sphingomyelin. I. Purification and properties of a sphingomyelin-cleaving enzyme from rat liver tissue. J Biol Chem. 1966; 241: 1081-1084.PubMedGoogle Scholar
  28. Klenk E. Uber die nature der phosphatide der milz bei Niemann-Pickschen Krankheit. Z Physiol Chem. 1934; 229: 151-156.Google Scholar
  29. Lieb H. Cerebrosidespeicherung bei Splenomegalie Typus Gaucher. Ztschr Physiol Chem. 1924; 140: 305-313.Google Scholar
  30. Marchand F. Über Sogennante idiopathische Splenomegalie (Typus Gaucher). Munchen med Wchnschr. 1907; 54: 1102-1103.Google Scholar
  31. Pentchev PG, Brady RO, Gal AE, Hibbert SR. Replacement therapy for inherited enzyme deficiency: sustained clearance of accumulated glucocerebroside in Gaucher’s disease following infusion of purified glucocerebrosidase. J Molec Med. 1975; 1: 73-78.Google Scholar
  32. Pentchev PG, Brady RO, Hibbert SR, Gal AE, Shapiro D. Isolation and characterization of glucocerebrosidase from human placental tissue. J Biol Chem. 1973; 248: 5256-5261.PubMedGoogle Scholar
  33. Sachs B. On arrested cerebral development with special reference to cortical pathology. J Nerv Ment Dis. 1887; 14: 541-553.Google Scholar
  34. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease. A randomized controlled trial. JAMA 2001; 285: 2743-2749.CrossRefPubMedGoogle Scholar
  35. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, et al. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA. 2000; 97: 365-370.CrossRefPubMedGoogle Scholar
  36. Steer CJ, Furbish FS, Barranger JA, Brady RO, Jones EA.The uptake of agalacto-glucocerebrosidase by rat hepatocytes and Kupffer cells. FEBS Lett. 1978 Jul 15; 91 (2): 202-205.CrossRefPubMedGoogle Scholar
  37. Tay W. Symmetrical changes in the region of the yellow spot in each eye of an infant. Trans Ophthal Soc UK. 1881: 1: 55-57.Google Scholar
  38. Thannhauser SJ. Diseases of cellular lipid metabolism. In: Christian HA (Ed.) Lipidoses, New York: Oxford University Press; 1950: 49.Google Scholar
  39. Trams EG, Brady RO. Cerebroside synthesis in Gaucher’s disease. J Clin Invest. 1960; 39: 1546-1560.CrossRefPubMedGoogle Scholar
  40. Van Den Hamer CJ, Morell AG, Scheinberg IH, Hickman J, Ashwell G. Physical and chemical studies on ceruloplasmin. IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation. J Biol Chem. 1970 Sep 10; 245(17): 4397-402.PubMedGoogle Scholar
  41. Weinreb NJ, Brady RO, Tappel AL. The lysosomal localization of sphingolipid hydrolases. Biochim Biophys Acta. 1968; 159: 141-146.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Roscoe O. Brady
    • 1
  1. 1.National Institute of Neurological Disorders and strokeNational Institutes of HealthBethesdaUSA

Personalised recommendations